[Asia Economy Reporter Ji Yeon-jin] Genexine announced on the 24th that it has licensed the technology of the sustained-release anemia treatment drug (GX-E4) to Indonesian pharmaceutical company KGBIO for $13 million (15.8 billion KRW).
The signing fee is $8 million (9.7 billion KRW), and $5 million (6.1 billion KRW) will be received as milestones.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
